Anavex Life Sciences has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its product, blarcamesine (ANAVEX®2-73), allowing the company to move forward with plans to study the investigational medication in individuals living with Fragile X syndrome (FXS).
What Happened?
The FDA has cleared Anavex’s IND application for blarcamesine, an investigational oral medication being developed for neurological conditions. The clearance gives the company the green light to advance its planned Phase 2a clinical trial in the United States.
Anavex plans to conduct a randomized, double-blind, placebo-controlled, dose-ranging Phase 2a study, identified as ANAVEX2-73-FXS-001. The planned study is expected to include approximately 60 adult males living with Fragile X syndrome.
Why Does This Matter?
There are currently no FDA-approved treatments that address the underlying cause of FXS. The FDA’s clearance allows Anavex to move forward with their clinical research plan to evaluate a new potential treatment approach.
FDA clearance of an IND is not FDA approval of a medication. Blarcamesine remains investigational, meaning it still needs to be studied in clinical trials so its safety and effectiveness for FXS can be explored.
What Are the Next Steps?
Anavex plans to conduct a Phase 2a clinical trial involving approximately 60 adult males living with Fragile X syndrome. The study will evaluate the medication’s safety, tolerability, and how the body processes it, with additional measures looking at behavior and cognition.
The results will help researchers determine whether blarcamesine warrants further investigation as a potential treatment for FXS.
At the NFXF, we’ll continue to follow Anavex’s progress and share updates as their research moves forward. Every step like this brings us closer to more options for our community.
Learn more:
Read Anavex’s full press release.
Note: Blarcamesine is an investigational medication and is not approved by the FDA to treat Fragile X syndrome. Its safety and effectiveness for FXS have not been established.
